Activaero | Date: 2010-08-03
The invention relates to a device for the flow rate limitation at low differential pressures, in particular for the limitation of the inhalation volume flow during the inhalation of therapeutic aerosols, comprising a housing with at least an inlet opening, at least an outlet opening and a flow channel arranged therebetween, wherein the flow channel is restricted by a flexible wall extending along the flow channel, characterised in that the flexible wall has a control area of less than 100 mm
Activaero | Date: 2013-01-15
Activaero | Date: 2010-02-03
Methods, devices and compositions for treatment of severe and uncontrolled asthma are provided by which high amounts of an inhaled corticosteroid are directed to the small airways of the lower lungs. The invention provides for a substantial decrease in the dose of concurrently administered oral corticosteroids. A particular advantage of the invention is the significant reduction in corticosteroid-related adverse effects.
Price D.,University of Aberdeen |
Bosnic-Anticevich S.,University of Sydney |
Briggs A.,University of Glasgow |
Chrystyn H.,University of Huddersfield |
And 3 more authors.
Respiratory Medicine | Year: 2013
Whilst the inhaled route is the first line administration method in the management of asthma, it is well documented that patients can have problems adopting the correct inhaler technique and thus receiving adequate medication. This applies equally to metered dose inhalers and dry powder inhalers and leads to poor disease control and increased healthcare costs. Reviews have highlighted these problems and the recent European Consensus Statement developed a call to action to seek solutions. This review takes forward the challenge of inhaler competence by highlighting the issues and suggesting potential solutions to these problems. The opportunity for technological innovation and educational interventions to reduce errors is highlighted, as well as the specific challenges faced by children. This review is intended as a policy document, as most issues faced by patients have not changed for half a century, and this situation should not be allowed to continue any longer. Future direction with respect to research, policy needs and practice, together with education requirements in inhaler technique are described. © 2012 Published by Elsevier Ltd.
Bennett W.D.,University of North Carolina at Chapel Hill |
Daviskas E.,Royal Prince Alfred Hospital |
Hasani A.,Royal Free Hospital |
Mortensen J.,Copenhagen University |
And 2 more authors.
Journal of Aerosol Medicine and Pulmonary Drug Delivery | Year: 2010
A workshop/symposium on "Mucociliary and Cough Clearance (MCC/CC) as a Biomarker for Therapeutic Development" was held on October 21-22, 2008, in Research Triangle Park, NC, to discuss the methods for measurement of MCC/CC and how they may be optimized for assessing new therapies designed to improve clearance of airway secretions from the lungs. The utility of MCC/CC as a biomarker for disease progression and therapeutic intervention is gaining increased recognition as a valuable tool in the clinical research community. A number of investigators currently active in using MCC/CC for diagnostic or therapeutic evaluation presented details of their methodologies. Attendees participating in the workshop discussions included those interested in the physiology of MCC/CC, some of who use in vitro or animal methods for its study, pharmaceutical companies developing muco-active therapies, and many who were interested in establishing the methods in their own clinical laboratory. This review article summarizes the presentations for the in vivo human MCC/CC methods and the discussions both at and subsequent to the workshop between the authors to move forward on a number of questions raised at the workshop. © Copyright 2010, Mary Ann Liebert, Inc. 2010.